ROS1 and non-small cell lung carcinoma: The kinase domains of ALK and ROS1 exhibit approximately 70% homology, accounting for the overlapping clinical characteristics observed in ALK-rearranged and ROS1-rearranged NSCLC, as well as their shared susceptibility to ALK/ROS1 inhibitors, including crizotinib and lorlatinib [88].